Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,451 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Parkinsonism Clear all

Conditions: Parkinson's Disease
Interventions: IPX066, CLE; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Fresno, California • Sunnyvale, California • Miami, Florida + 9 more

Conditions: Parkinson Disease
Interventions: DaTscan; Drug
Lead sponsor: Ken Marek, MD; Other
Eligibility: 30 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 21
States / cities: Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more

Conditions: Parkinson Disease, Parkinsonism, Dyskinesias
Interventions: Zonegran; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson's Disease
Interventions: SKY Breath and Meditation; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Coral Springs, Florida • Davie, Florida • Fort Lauderdale, Florida

Conditions: Parkinson Disease
Interventions: Hydrogen, Placebo oral tablet; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Stress, Anxiety, Depression, Parkinson Disease
Interventions: Isha Kriya, Nadi Shuddhi, Nada Yoga, Routine Daily Activity; Behavioral · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson's Disease
Interventions: Peripheral Nerve Tissue Implantation; Procedure
Lead sponsor: Craig van Horne, MD, PhD; Other
Eligibility: 40 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Early Stage Parkinson Disease
Interventions: Pardaprunox, pramipexole, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more

Conditions: Orthostatic Hypotension, Idiopathic Parkinson Disease
Interventions: Droxidopa 100 MG [Northera]; Drug
Lead sponsor: Alberto Espay, MD, MSc; Other
Eligibility: 30 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Parkinson Disease
Interventions: Vibrotactile coordinated reset; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Parkinson Disease
Interventions: Active LIFUP Treatment, Sham LIFUP Treatment; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Parkinson Disease
Interventions: Glucose; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Parkinson's Disease
Interventions: Gait training; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinsons Disease
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Daniel Burdick, MD; Individual
Eligibility: 30 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Parkinson Disease Psychosis
Interventions: AGB101; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson Disease, Depressive Symptoms
Interventions: BIOPAC Stimsola, BIOPAC Stimsola Sham (zero amps); Device
Lead sponsor: University of South Alabama; Other
Eligibility: 19 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Parkinson's Disease
Interventions: Istradefylline; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Parkinson's Disease
Interventions: AFQ056 with L-dopa, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: The Parkinson's Institute; Other
Eligibility: Up to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Parkinson's Disease
Interventions: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg); Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 45 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parkinson's Disease, Off Episodes of Parkinson Disease
Interventions: APL-130277, Placebo, Moxifloxacin; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 10
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more

Conditions: Parkinson Disease
Interventions: collection of LFPs; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 30 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease

Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease

Efficacy of a Breathwork Practice (SKY) on Well-Being of Individuals With Parkinson's Disease (iPD) and Care Partners

Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease

Yoga for Mental Health in Parkinson's Patients

Biological Markers in Parkinson's Disease

Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Lundbeck TOMs Orthostatic Hypotension

Vibrotactile Coordinated Reset for the Treatment of Advanced Parkinson's Disease

LIFUP for Treatment of Motor Deficits in Parkinson's Disease

Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients

Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

Low Voltage Electrical Stimulation for Depression in Parkinson's Patients

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

High Order Spectral Analysis of Local Field Potential Data on a Subgroup of Parkinson's Disease Patients Who Are Carriers of Mutations in the Glucocerebrosidase (GBA) Gene Undergoing DBS Electrode Placement